Adstiladrin Suspension
FDA Label NDC 55566-1050

26 label sections · Submitted to the FDA by Ferring Pharmaceuticals Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Ferring Pharmaceuticals Inc. for the product Adstiladrin (NDC 55566-1050). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2 dosage and administration, 2.1 dose, 2.2 preparation and handling, 2.3 bladder instillation of adstiladrin, 3 dosage forms and strengths, 4 contraindications, 5.1 risk of muscle invasive or metastatic bladder cancer with delayed cystectomy, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.